Buy PT-141 20 mg Pen in South Africa
PT-141 (bremelanotide), 20 mg per click pen, studied in libido and arousal research. Each click delivers 67 µg from a 3 mL · 300-click pen.
how many clicks
for your dose?
This PT-141 20 pen holds 20 mg across 300 clicks, so each click delivers 67 µg. Tap a dose or turn the dial; we'll count the clicks. For research reference only.
why researchers chose this pen
chose it for the click dosing, no syringes, no unit maths.
verified purity, checked against the public CoA before first use.
precise clicks in every 3 mL pen, the whole protocol in one barrel.
re-order or refer a colleague within three months.
about the
PT-141 20 pen
PT-141 (bremelanotide) is a melanocortin receptor agonist, supplied in a 3 mL / 300-click pen for research.
Certificate of analysiswhy a pen beats
a vial & syringe
Traditional research peptides arrive as lyophilised powder that must be reconstituted, drawn into insulin syringes, and converted from milligrams to units by hand, every step a chance for a dosing error.
A multi-dose pen removes the whole failure chain. The peptide arrives already dissolved and calibrated. Attach a fresh needle, turn the dial until you count your clicks, and you're done, the same audible-click mechanism trusted in insulin and GLP-1 pens worldwide.
Pens travel and store better, too: no open vials, no bent needles, no septum contamination after repeated draws. One sealed barrel, ten sterile needles, one dosing card.
how to buy
peptides safely
The peptide market has a purity problem: independent surveys routinely find underdosed, mislabelled or contaminated product sold online. The only reliable defence is third-party verification you can check yourself, not a supplier's own claims.
Before buying any peptide pen, ask three questions. Is every batch tested by an independent lab? Is the certificate of analysis available, so you can check your exact lot before first use? And does it ship cold-chain, insulated and gel-packed, so what was tested is what arrives?
Veyvora answers yes on every order, independent assay, a CoA on request against the batch number, and cold dispatch within 24 hours, paperwork packed inside.
pairs well with
view all
Overview
Veyvora’s PT-141 20 mg research pen supplies bremelanotide in a multi-dose format for controlled in-vitro laboratory work. This page covers what the pen contains and how its specification is documented, what batch-level evidence to request before purchase, and how to handle and store the pen. Current ZAR pricing and live stock status are confirmed at checkout. To proceed directly to the product listing, use the Purchase PT-141 button on the Veyvora product page.
Bremelanotide is a synthetic cyclic heptapeptide that acts as a melanocortin-receptor agonist, specifically at MC4R (melanocortin 4 receptor), and reached clinical development as the basis for Vyleesi, a 1.75 mg subcutaneous autoinjector the US Food and Drug Administration (FDA) approved on 21 June 2019 [1]. The Veyvora research pen is a separate laboratory preparation supplied for in-vitro research.
Every batch is verified by two independent laboratories using high-performance liquid chromatography (HPLC), mass spectrometry and an endotoxin assay, with a public certificate of analysis (CoA) available for batch-level confirmation (Veyvora product specification, accessed 2026). That documentation chain is what researchers weigh when evaluating this product.
Key Takeaways
- The pen contains 20 mg bremelanotide in a 3 mL multi-dose device delivering approximately 67 µg per click across 300 clicks.
- Batch-level CoAs verified by HPLC, mass spectrometry and endotoxin assay are publicly available; confirm the batch identifier and laboratory name before purchase.
- The product is supplied for in-vitro laboratory research; complete the laboratory’s chemical-safety risk assessment under the Regulations for Hazardous Chemical Agents, 2021 before use.
- Pricing, VAT treatment, stock status and territory eligibility are confirmed directly on the Veyvora product page at the point of purchase.
Product Identity and Scope
Veyvora’s PT-141 20 mg research pen contains bremelanotide, a synthetic cyclic heptapeptide melanocortin-receptor agonist with primary affinity for MC4R, supplied as a multi-dose pen format for controlled in-vitro laboratory use. The pen delivers 20 mg of bremelanotide across 300 clicks in a 3 mL multi-dose device, with each click stated to release approximately 67 µg, based on Veyvora’s 2026 product specification.
Bremelanotide reached clinical authorisation as Vyleesi, a 1.75 mg subcutaneous autoinjector the US FDA approved on 21 June 2019 [1]. The Veyvora research pen is a separate laboratory preparation with a larger total fill and click-based dispensing.
Confirm the labelled quantity, batch number and CoA against the current product listing before purchase.
Verified Specifications
The pen is stated to contain 20 mg of bremelanotide in a 3 mL multi-dose format, delivering approximately 67 µg per click across 300 clicks, based on Veyvora’s 2026 product specification. These figures are drawn from the supplier’s product listing; the batch CoA reports the measured results for the lot supplied.
The table below presents the specification as stated by Veyvora. Values marked [confirm with operator] are reported on the current product page or batch certificate; read them there before purchase.
| Parameter | Stated value | Source |
|---|---|---|
| Active substance | Bremelanotide (PT-141) | Veyvora 2026 product listing |
| Total content per pen | 20 mg | Veyvora 2026 product listing |
| Fill volume | 3 mL | Veyvora 2026 product listing |
| Clicks per pen | 300 | Veyvora 2026 product listing |
| Dose per click | ~67 µg | Veyvora 2026 product listing |
| Solvent / excipients | [confirm with operator] | — |
| Needle gauge | [confirm with operator] | — |
| Stated purity | [confirm with operator] | — |
For comparison, the US-approved medicine Vyleesi is specified as 1.75 mg bremelanotide in 0.3 mL as a single-dose autoinjector [1]; the Veyvora research pen is a laboratory presentation with a single 20 mg fill dispensed in 300 clicks. Cross-reference the current listing against the batch certificate before committing to a purchase. For research-peptide storage guidance that accompanies these specifications, see Veyvora’s handling page.
Batch Documentation and Analytical Evidence
A CoA is matched to the specific batch it names: the document states the batch identifier, test date, analytical method and the name of the testing laboratory, which is how it verifies the pen in hand. Veyvora states that every batch is checked by two independent laboratories using HPLC, mass spectrometry and endotoxin assay, with a public CoA available for batch verification (Veyvora 2026 product positioning). Request the CoA for your lot and read it before use.
Reading the Certificate of Analysis
HPLC purity reports the proportion of the target compound relative to detectable peaks under the conditions used. Mass spectrometry confirms molecular identity, and the endotoxin assay reports the endotoxin level for the lot; each line of the certificate answers one analytical question. For a plain-language account of how HPLC purity figures are measured and reported, see what HPLC purity does and does not prove.
Where a testing laboratory states SANAS (South African National Accreditation System) accreditation, its status can be checked in the SANAS Directory of Accredited Facilities at https://www.sanas.co.za/ [2].
Handling and Storage
Take the storage and in-use instructions for the pen from the current Veyvora product page or the CoA supplied with your order.
Peptide solutions are sensitive to light, heat and repeated freeze–thaw cycles, all of which degrade the analyte by breaking peptide bonds and promoting aggregation. Veyvora states that PT-141 pens are dispatched in insulated, gel-packed 2–8 °C mailers fitted with a temperature indicator strip, and that dispatch occurs within 24 hours of order (Veyvora 2026 product positioning). Check the indicator strip on arrival and keep it with the batch record.
The US-approved medicine Vyleesi (bremelanotide 1.75 mg subcutaneous autoinjector) carries its own FDA-approved storage conditions [1], a useful reference point for the same molecule in a different formulation and device; the research pen’s own conditions are stated in its documentation.
For confirmed handling protocols once your pen arrives, see Veyvora’s research-peptide storage guidance.
Ordering Information
Current ZAR pricing, stock status, available pack sizes, VAT treatment, courier details and territory terms for the Veyvora PT-141 20 mg research pen are shown on the current Veyvora product page; take those figures from the product page at the point of purchase.
What to Confirm Before Placing an Order
Before completing a purchase, verify the following directly with Veyvora:
- Current R price and whether VAT is included or added at checkout
- Available pack sizes and any minimum order quantity for distributor accounts
- Stock availability and estimated dispatch lead time
- Delivery territory: whether Veyvora ships to your specific South African postcode or institution
- Invoice wording: confirm the invoice reflects research-only supply
Research Use
The Veyvora PT-141 20 mg research pen is supplied for in-vitro laboratory research, such as melanocortin-receptor binding and signalling assays, cell-culture work and use as an analytical reference material. Not for human or veterinary use. Bremelanotide is the active substance of the US-approved medicine Vyleesi [1]; no bremelanotide medicine is registered in the SAHPRA Registered Health Products Database as of 2026 [3], and this research pen is a separate laboratory presentation.
Related Research and Comparison Pages
The pages below extend specific points made on this product page.
For a step-by-step process of matching a batch certificate to the pen you receive, see how to match a CoA to your pen, covering batch ID, test date, and laboratory name against the document Veyvora supplies. For a clear account of how HPLC purity figures are measured and what they report, what HPLC purity does and does not prove covers the analytical method.
Bremelanotide’s widely authorised finished medicine is Vyleesi, which the US FDA approved on 21 June 2019 as a 1.75 mg subcutaneous autoinjector [1]. South African registration status can be checked against the SAHPRA Registered Health Products Database on the date of purchase; the database returned no record for bremelanotide as of 2026 [3].
To place an order for the PT-141 20 mg research pen, visit Veyvora’s research-peptide catalogue directly and confirm current pricing, stock, and territory eligibility before proceeding.
Sources
[1] accessdata.fda.gov, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf [2] South African National Accreditation System (SANAS), Directory of Accredited Facilities, sanas.co.za, https://www.sanas.co.za/ [3] SAHPRA Registered Health Products Database, sahpra.org.za, https://medapps.sahpra.org.za:6006/
